News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
Partner Content Partner Content World Biosimilars Market will surge at 27%+ CAGR up to 2025 Biosimilars Market will surpass USD 69 billion by 2025
News ESC26: Can Arrowhead pierce Ionis' triglyceride armour? Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
